Valuation: Sharp Therapeutics Corp.

Market Cap 30.85M 27.52M 25.64M 23.33M 43.94M 2.97B 44.27M 310M 121M 1.52B 116M 113M 4.87B P/E 2024
-2.2x
P/E 2025 -8.7x
Enterprise Value 31.18M 27.81M 25.91M 23.58M 44.41M 3B 44.74M 313M 122M 1.53B 117M 115M 4.93B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.38%
Yield 2024 *
-
Yield 2025 -
08-28 Sharp Therapeutics Corp. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
07-29 Sharp Therapeutics Corp. announced that it has received CAD 1.365 million in funding from Newlin Investment Company 1, LLC CI
07-29 Sharp Therapeutics Raises C$1.37 Million Via Non-Brokered Private Placement MT
07-15 Sharp Therapeutics Corp. announced that it expects to receive CAD 1.365 million in funding from Newlin Investment Company 1, LLC and other investors. CI
05-28 Sharp Therapeutics presents new preclinical data supporting novel small-molecule therapeutic approach for Niemann-Pick disease type C RE
05-28 Sharp Therapeutics Corp Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C CI
04-17 Sharp Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-16 Sharp Therapeutics Corp. Auditor Raises 'Going Concern' Doubt CI
04-16 Sharp Therapeutics Corp. announced that it has received $1.55 million in funding from Stx Partners, Llc, Newlin Investment Company 1, LLC, Brooks Family Office LLC CI
04-15 Sharp Therapeutics Corp. announced that it expects to receive $15 million in funding from Stx Partners, Llc and more investors. CI
04-10 Sharp Therapeutics Corp. Provides Updates on ?901 for Gaucher and GBA1 Parkinson?s and Platform Programs CI
02-02 Sharp Therapeutics to Raise US$3 Million Through a Convertible Notes Offering MT
02-01 Sharp Therapeutics Corp. announced that it expects to receive $3 million in funding from Stx Partners, Llc, Newlin Investment Company CI
1 month+50.55%
3 months+50.55%
6 months-36.28%
Current year-45.20%
1 month 1.37
Extreme 1.37
1.38
Current year 0.91
Extreme 0.91
2.4
1 year 0.91
Extreme 0.91
5
3 years 0.23
Extreme 0.23
5
5 years 0.23
Extreme 0.23
5
10 years 0.23
Extreme 0.23
5
Date Insider Type Main position Quantity % Market Cap. Importance
29/07/26 Sell

Chairman

307,693 0.9745%
22/04/26 Sell

Director

200,000 0.6664%
10/04/26 Sell

Director

200,000 0.6664%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+98.55%+24.55% 30.37M
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.82%-2.48%+21.71%+76.95% 56.95B
+2.38%+1.20%+6.07%+37.76% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.77%-0.14%+59.40%+118.22% 39.36B
Weighted average by Cap. +2.18%-0.46%+58.99%+137.10%

Financials

2024 2025
Net sales - -
Net income -3.26M -2.91M -2.71M -2.47M -4.64M -314M -4.68M -32.75M -12.74M -160M -12.24M -11.98M -515M -6.17M -5.51M -5.13M -4.67M -8.79M -595M -8.86M -62M -24.12M -303M -23.18M -22.68M -975M
Net Debt -2.17M -1.93M -1.8M -1.64M -3.09M -209M -3.11M -21.78M -8.47M -107M -8.14M -7.97M -343M 326K 291K 271K 247K 464K 31.39M 468K 3.27M 1.27M 16.02M 1.22M 1.2M 51.5M
Logo Sharp Therapeutics Corp.
Sharp Therapeutics Corp. is a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases. Its discovery platform combines high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. Its technology includes CoreX assay technology, AlloChem compound libraries, and mine data system and machine learning layer. Its advanced programs include a small molecule that prevents the degradation of the neuroprotective protein progranulin, thus increasing progranulin levels preventing neurodegeneration, and a small molecule that restores activity of mutated GCase protein (mutation and loss of activity of GCase is the genetic cause of Gaucher’s disease).
Employees
-
  1. Stock Market
  2. Stocks
  3. SHRX Stock